Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies
Pedro Piccardo , Larisa Cervenakova, Irina Vasilyeva, Oksana Yakovleva, Igor Bacik, Juraj Cervenak, Carroll McKenzie, Lubica Kurillova, Luisa Gregori, Kitty Pomeroy, and David M. Asher
Author affiliations: University of Edinburgh, Easter Bush, UK, (P. Piccardo); Food and Drug Administration, Kensington, Maryland, USA (P. Piccardo, I. Bacik, J. Cervenak, L. Kurillova, L. Gregori, K. Pomeroy, D.M. Asher); Holland Laboratory American Red Cross, Rockville, Maryland, USA (L. Cervenakova, I. Vasilyeva, O. Yakovleva, C. McKenzie)
Figure 3. Western blot of recombinant prion protein (PrP) 5 ng (lane 1), CHO cells (lanes 2–5) and Vero cell (lanes 6–9). Cells exposed to normal bovine brain and passaged 30 times (lanes 2, 3, 6, 7). Cells exposed to bovine spongiform encephalopathy agent and passaged 30 times (lanes 4, 5, 8, 9). Total PrP (cell extracts without proteinase K [PK] digestion) are shown in lanes 2, 4, 6, 8; cell extracts treated with PK are shown in lanes 3, 5, 7, 9. Western blots were probed with PrP monoclonal antibody 6D11.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.